# What Cannabis Does to Heart Rate and Blood Pressure, and Which Patients Should Take That Seriously > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-heart-rate-and-blood-pressure-effects/ > **Published:** 2026-09-04T22:52:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:51-04:00 > **Clinical Summary:** Cannabis raises heart rate and shifts blood pressure within minutes. What the cannabis heart rate and blood pressure evidence means for cardiac patients. --- CED Clinical Relevance #64High Safety RelevanceCardiovascular history is one of the few areas where a cannabis conversation should change a clinical plan rather than simply document a behavior. The acute hemodynamic effects are well characterized and the population risk signal has been reproduced across several designs. Cannabis has a measurable effect on the circulatory system within minutes, and a population-level association with major cardiovascular events that has now appeared in multiple independent analyses. Neither of those facts is controversial. What is contested is how much of the population signal reflects cannabis itself, and that uncertainty is not a reason to downplay it. Clinical Insight | CED Clinic Smoking cannabis produces a dose-dependent rise in heart rate, elevated blood pressure while lying down, and a fall in blood pressure on standing. Those are the hemodynamic effects described in the cardiology literature, not side effects that occur occasionally. A 2025 systematic review and meta-analysis in *Heart* pooled 24 pharmacoepidemiological studies and reported elevated risk estimates for acute coronary syndrome, stroke, and cardiovascular death among people who use cannabis. [Cardiovascular Safety](https://cedclinic.com/cbd-cardiovascular-effects-gummies-heart-health/)Blood PressureHeart RateCannabis RiskClinical Research AudiencePatients with cardiovascular risk, caregivers, and cliniciansPrimary TopicCannabinoid effects on heart rate, blood pressure, and cardiovascular riskSource[Read the full source](https://doi.org/10.1136/heartjnl-2024-325429) Why This Matters Most patients discussing cannabis with a physician are discussing pain, sleep, or anxiety. Very few raise the circulatory system, and very few clinicians ask. That omission matters most in exactly the population where it is easiest to miss: an adult with coronary disease, hypertension, or an arrhythmia who is quietly using cannabis for something else entirely. The acute effects are predictable enough to plan around, and the risk literature is consistent enough in direction that a cardiac history should change how a cannabis conversation goes. Those are two different arguments and both are worth making. The First Hour: What Cannabis Does to Circulation The acute hemodynamic profile of smoked cannabis has been described in the cardiology literature for decades. Writing in *Circulation*, Murray Mittleman and colleagues summarized it as a dose-dependent increase in heart rate, supine hypertension, and postural hypotension. In plain terms: the heart speeds up, blood pressure rises while the person is lying down, and blood pressure falls when they stand. Mechanistically this is [CB1 receptor](https://cedclinic.com/cbd-gummies-and-psychosis-risk/) activity interacting with autonomic control of the cardiovascular system. The tachycardia is the most reliable and most easily measured effect, and it is the one a patient is most likely to notice and describe as their heart pounding. The postural drop is the one that produces the lightheadedness on standing that new users frequently report and that can produce a fall in an older patient. The American Heart Association addressed this directly in a 2020 scientific statement in *Circulation*, which reviewed medical and recreational cannabis from a cardiovascular perspective and concluded that while cannabis may have therapeutic benefits, few of them are cardiovascular in nature, and that many of the concerning health implications are. Cannabidiol Is Not Hemodynamically Neutral Either CBD is often presented as the component with no cardiovascular activity. A randomized, placebo-controlled crossover study published in *JCI Insight* tested that assumption. Nine healthy male volunteers received a single 600 mg dose of cannabidiol or placebo with continuous cardiovascular monitoring. CBD reduced resting systolic blood pressure by about 6 mmHg and stroke volume by about 8 mL, with a compensatory increase in heart rate and maintained cardiac output. Before and after a stress task, systolic pressure was about 5 mmHg lower and heart rate about 10 beats per minute higher on CBD. In response to a cold stress challenge, the blood pressure rise was blunted by about 6 mmHg with a 7 beat per minute heart rate increase and lower total peripheral resistance. This is a nine-person single-dose study in healthy young men, which limits how far it generalizes. It does establish that CBD has measurable hemodynamic activity, which matters for a patient already taking antihypertensive medication and for anyone who assumes the non-intoxicating cannabinoid carries no circulatory effect at all. The Trigger Signal: Risk in the Hour After Use The best-known study of acute cardiac risk is the Determinants of Myocardial Infarction Onset Study, reported by Mittleman and colleagues in *Circulation*. Investigators interviewed 3,882 patients an average of four days after an acute myocardial infarction and used a case-crossover design, which compares each patient’s exposure in the hour before symptoms began against their own usual frequency of that exposure. Of those 3,882 patients, 124 reported smoking cannabis in the prior year, 37 within 24 hours, and 9 within one hour of symptom onset. The risk of infarction onset was elevated 4.8 times over baseline in the 60 minutes after cannabis use, with a 95 percent confidence interval from 2.4 to 9.5, and the elevation fell off rapidly after that window. Two things are true at once here. The relative risk in that hour is substantial, and the absolute event is rare, which is how the authors themselves framed it. For a healthy 25-year-old the absolute risk remains very small. For someone with established coronary disease, a transient fivefold multiplier on an already elevated baseline is a different calculation entirely. The Population Signal Has Been Reproduced A 2024 analysis in the *Journal of the American Heart Association* used Behavioral Risk Factor Surveillance System data from 27 states and two territories, covering 434,104 respondents aged 18 to 74. Daily cannabis use was reported by 4 percent and non-daily use by 7.1 percent. After adjustment for tobacco use and other characteristics, daily cannabis use was associated with myocardial infarction at an adjusted odds ratio of 1.25, stroke at 1.42, and a composite of coronary heart disease, myocardial infarction, and stroke at 1.28, with lower odds at intermediate frequencies of use. The result that resists the easiest objection is the never-tobacco-smoker analysis. Among respondents who had never smoked tobacco, daily cannabis use was associated with myocardial infarction at an odds ratio of 1.49, stroke at 2.16, and the composite at 1.77. Relationships were similar in men under 55 and women under 65, the groups at risk of premature cardiovascular disease. A systematic review and meta-analysis published in *Heart* in 2025 pooled 24 pharmacoepidemiological studies. The estimated risk ratios were 1.29 for acute coronary syndrome, 1.20 for stroke, and 2.10 for cardiovascular death. A sensitivity analysis restricted to cohort studies gave a comparable result of 1.32. The authors concluded that these findings should encourage investigating cannabis use in every patient presenting with a serious cardiovascular disorder. Where the Evidence Is Genuinely Contested Not every analysis agrees, and the disagreements are worth stating rather than skipping. A separate meta-analysis of 17 observational studies covering 1,902,481 individuals found no statistically significant association between ever using cannabis and myocardial infarction alone, with a risk ratio of 1.25 and a confidence interval from 0.91 to 1.71, nor with stroke alone at 1.38 with an interval from 0.88 to 2.16. The composite of any adverse cardiovascular event was significant at 1.48. A two-sample Mendelian randomization study, which uses genetic variants associated with cannabis use to reduce confounding, found no causal effect of genetically predicted cannabis use on coronary artery disease, myocardial infarction, stroke, atrial fibrillation, or heart failure. After adjusting for tobacco use and body mass index, a multivariable analysis did suggest an effect on small vessel stroke and on atrial fibrillation. The honest reading is that the observational signal is consistent in direction and inconsistent in magnitude, that ever-use is a poor exposure measure while frequency of use behaves more like a dose, and that no design has cleanly separated cannabis from tobacco, from combustion, and from the health characteristics of people who use cannabis daily. That is a case for uncertainty about size, not for dismissal. What This Supports Doing For a patient with no cardiac history and no risk factors, the acute effects are the practical issue: expect a faster heart rate, expect lightheadedness on standing, stand up slowly, and know that the effect is larger with inhaled routes because peak concentrations arrive faster. For a patient with coronary disease, prior myocardial infarction, poorly controlled hypertension, an arrhythmia history, or prior stroke, cannabis belongs in the cardiology conversation rather than in a separate lane. That is true whether the product is medical or recreational and whether the reason for use is pain, sleep, or anything else. Combustion adds a well-established insult to the vasculature that has nothing to do with cannabinoids and is avoidable by changing route. The clinical ask is modest and specific. Ask about cannabis by name during cardiac evaluation, record frequency rather than a yes or no, and treat daily use as the exposure category the risk data actually describe. Patients rarely volunteer it, and the evidence above is the reason that silence is a problem. Study SnapshotAnchor ReviewCardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysisDesignSystematic review of pharmacoepidemiological studies published January 2016 to January 2023; random effects meta-analysis; PROSPERO CRD42023401401Included Studies24 articles from 3,012 records: 17 cross-sectional, 6 cohort, 1 case-controlPooled EstimatesAcute coronary syndrome RR 1.29 (95% CI 1.05 to 1.59); stroke RR 1.20 (1.13 to 1.26); cardiovascular death RR 2.10 (1.29 to 3.42)Cohort-Only AnalysisRR 1.32 (95% CI 1.01 to 1.73), comparable to the primary modelJournalHeart 2025;111(22):1047-1056PMID / DOI40527600 / 10.1136/heartjnl-2024-325429Acute Trigger DataMittleman et al., Circulation 2001;103(23):2805-2809; 3,882 infarction patients, risk elevated 4.8-fold (95% CI 2.4 to 9.5) in the 60 minutes after cannabis use (PMID 11401936)Population SurveyJeffers et al., Journal of the American Heart Association 2024;13(5):e030178; 434,104 respondents; daily use aOR 1.25 myocardial infarction, 1.42 stroke, 1.28 composite; among never-tobacco smokers 1.49, 2.16, and 1.77 (PMID 38415581)CBD HemodynamicsJadoon et al., JCI Insight 2017;2(12):e93760; single 600 mg dose lowered resting systolic pressure about 6 mmHg and raised heart rate, n=9 healthy men (PMID 28614793)Guideline ContextPage et al., Circulation 2020;142(10):e131-e152, American Heart Association scientific statement on cannabis and cardiovascular health (PMID 32752884) How Strong Is This Evidence? The acute hemodynamic evidence is strong and old. Heart rate response, supine pressure rise, and postural drop have been reproduced in controlled human administration studies for decades and are not in dispute. The chronic risk evidence is observational and consistent in direction. Several independent designs, including a meta-analysis of pharmacoepidemiological studies and a large survey analysis restricted to people who never smoked tobacco, point the same way. Consistency across designs is meaningful even when each individual design has limits. Where This Paper Deserves Skepticism Most of the population evidence is cross-sectional and relies on self-reported cannabis use and self-reported cardiovascular events, which invites both misclassification and reverse causation. A person who had a heart attack may recall and report use differently than someone who did not. Mendelian randomization, which is less vulnerable to confounding, did not support a causal effect on most cardiovascular outcomes, though it did suggest one for small vessel stroke and atrial fibrillation after adjustment. And a separate meta-analysis found ever-use not significantly associated with myocardial infarction or stroke individually. Magnitude remains genuinely uncertain. What This Paper Does Not Show None of this establishes that cannabis causes myocardial infarction or stroke in any individual patient, nor does it quantify absolute risk for a specific person. Relative risk estimates without an individual baseline are not a personal risk calculation. The literature also does not separate route cleanly. Combustion carries its own vascular toxicity, and few studies have enough non-inhaled exposure to say whether oral or vaporized products carry the same signal. How This Fits With the Broader Clinical Conversation Cardiovascular risk is the area where [cannabis medicine](https://cedclinic.com/cbd-gummies-smoking-cessation/) most resembles early tobacco research: a consistent observational signal, a plausible acute mechanism, contested causal inference, and a long lag before the question is settled. The tobacco comparison is about the shape of the evidence, not the size of the effect, which appears considerably smaller here. It is also the area where the gap between how patients think about cannabis and how cardiologists think about it is widest. A patient using an edible for arthritis pain does not file that under heart health. The evidence says it belongs there, at least for the conversation. Dr. Caplan’s Take This is one of the few places in cannabis medicine where I will discourage a patient rather than help them optimize. If someone is a year out from a stent and using cannabis daily, the conversation is not about which product. It is about whether daily use is a good idea at all, and what the alternative plan for their symptom is. The tachycardia gets dismissed too easily because it is transient and because experienced users stop noticing it. Partial tolerance to the cardiac response develops, but partial is the operative word, and a patient who no longer feels their heart racing has not stopped having the response. The other thing I say often: route matters and it is the easiest variable to change. If a patient with vascular disease is going to use cannabis, smoking it is the version I have the least tolerance for, because combustion adds a harm that has nothing to do with the cannabinoid and is entirely avoidable. Clinical Bottom Line Cannabis reliably raises heart rate, raises blood pressure while supine, and lowers it on standing. Multiple independent analyses associate cannabis use, and daily use in particular, with higher rates of acute coronary syndrome, stroke, and cardiovascular death, including among people who never smoked tobacco. The magnitude is uncertain. The direction is not. Anyone with cardiac disease or meaningful cardiovascular risk should discuss cannabis with their clinician before using it, and should treat frequency of use as the variable that matters most. What a Careful Reader Should Take Away Read the frequency gradient rather than the yes-or-no comparison. The survey evidence found the strongest associations with daily use and proportionally lower odds at fewer days per month, which is the pattern you would expect if the exposure were doing something. Ever-use analyses, which lump a college experiment in with twenty years of daily smoking, are the ones that most often come back null. Evidence Interpretation Guide Table of Contents - [How to weigh an observational cardiovascular signal](#How_to_weigh_an_observational_cardiovascular_signal) - [Cannabis and the Circulatory System, Seen From Eight Angles](#Cannabis_and_the_Circulatory_System_Seen_From_Eight_Angles)[If you have a heart condition, this is a conversation to start](#If_you_have_a_heart_condition_this_is_a_conversation_to_start) - [Add it to the cardiac history, not to a separate lane](#Add_it_to_the_cardiac_history_not_to_a_separate_lane) - [The null results deserve airtime too](#The_null_results_deserve_airtime_too) - [What the designs can and cannot carry](#What_the_designs_can_and_cannot_carry) - [This is not a new observation](#This_is_not_a_new_observation) - [The variables a patient can actually change](#The_variables_a_patient_can_actually_change) - [What would resolve the magnitude question](#What_would_resolve_the_magnitude_question) - [Labeling says nothing about the heart](#Labeling_says_nothing_about_the_heart) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to weigh an observational cardiovascular signal The Research QuestionIs cannabis use associated with major adverse cardiovascular events, and how large is the association?The Patient QuestionI have heart problems and I use cannabis for something else. Does that matter, and what should I do about it?The Bottom LineThe acute hemodynamic effects are established fact. The chronic risk association is consistent across designs and uncertain in size. Both belong in a cardiac patient’s conversation with their clinician. CED Perspective Lens ## Cannabis and the Circulatory System, Seen From Eight Angles Acute hemodynamics and population risk data, read through the lenses that matter in clinical practice. Lens OverviewCannabis produces a dose-dependent rise in heart rate with supine hypertension and postural hypotension, and pooled pharmacoepidemiological data associate its use with higher rates of acute coronary syndrome, stroke, and cardiovascular death. #### If you have a heart condition, this is a conversation to start Cannabis speeds the heart up and shifts blood pressure within minutes, and the effect is larger when it is inhaled because concentrations peak faster. Lightheadedness on standing is common and is a fall risk in older adults. If you have coronary disease, an arrhythmia, uncontrolled blood pressure, or a prior stroke, tell your cardiologist you use cannabis and tell them how often. Frequency is the part the risk research is actually about. Lens takeawayReport cannabis use by frequency, not as a yes or no, to anyone managing your heart. #### Add it to the cardiac history, not to a separate lane The 2025 Heart meta-analysis concluded explicitly that these findings should encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders. That is a workflow recommendation, not a mechanistic claim. Record days of use per month rather than a binary. The survey data show a frequency gradient, and a binary field discards the variable that carries the signal. Lens takeawayAsk by name, record frequency, and treat daily use as the exposure the data describe. #### The null results deserve airtime too A meta-analysis of 17 observational studies covering more than 1.9 million people found no statistically significant association between ever using cannabis and myocardial infarction or stroke taken separately, though the composite outcome was significant. A Mendelian randomization analysis found no causal effect on most common cardiovascular outcomes, with the exception of small vessel stroke and atrial fibrillation after adjustment for tobacco and body mass index. Lens takeawayUncertainty about magnitude is real. It is not the same as absence of a signal. #### What the designs can and cannot carry Cross-sectional surveys with self-reported exposure and self-reported outcomes cannot establish sequence, and people who use cannabis daily differ from people who do not in ways no adjustment fully captures. The case-crossover design used in the trigger study is better suited to acute risk because each patient serves as their own control, but it rested on nine patients who used cannabis within the hour before symptoms, which is why the confidence interval is wide. Lens takeawayRead the acute data as mechanism and the population data as direction, not as an individual risk estimate. #### This is not a new observation The acute hemodynamic profile of cannabis was characterized well before the current wave of legalization, and the case-crossover infarction study appeared in Circulation in 2001. What changed was exposure prevalence, product potency, and the availability of large datasets. The 2020 American Heart Association scientific statement consolidated this literature and reached a blunt conclusion: cannabis may have therapeutic benefits, but few of them are cardiovascular. Lens takeawayThe signal predates legalization. The scale of the exposed population is what is new. #### The variables a patient can actually change Route is the most modifiable. Combustion adds vascular injury that has nothing to do with cannabinoids, and switching away from smoking removes that layer without removing the therapeutic component. Frequency is the second. The survey data associate the largest odds with daily use and proportionally lower odds at fewer days per month, which makes reduced frequency a meaningful lever rather than a moral one. Lens takeawayChange the route first, then the frequency. Both are measurable. #### What would resolve the magnitude question Prospective cohorts with verified exposure, route information, and adjudicated cardiovascular endpoints would do more than another cross-sectional survey. Exposure measured as frequency and dose rather than ever-use is the minimum requirement. Studies that can compare inhaled against oral exposure would separate combustion from cannabinoid, which is currently the largest unresolved confounder in the field. Lens takeawayBetter exposure measurement, not more studies, is what this literature needs. #### Labeling says nothing about the heart Regulated markets require potency labeling and warnings that rarely mention cardiovascular effects. A patient with coronary disease buying a product in a dispensary receives no signal that their history is relevant. Given the consistency of the association across designs, cardiovascular caution has a reasonable claim to appear alongside the pregnancy and driving warnings already in place. Lens takeawayCardiovascular history is absent from most point-of-sale warnings and has a case for inclusion. Related Reading at CED ClinicContinue exploring the evidence[Understanding Cannabis and Acute Coronary Syndrome](https://cedclinic.com/cannabis-acute-coronary-syndrome-mechanisms-review/) The mechanistic review behind the coronary outcomes summarized here. [Read the mechanisms review](https://cedclinic.com/cannabis-acute-coronary-syndrome-mechanisms-review/)[Cannabis Heart Rhythm, Peer-Reviewed at Last: The JACC Data](https://cedclinic.com/cannabis-heart-rhythm-jacc-study/) The arrhythmia side of the same question, with its own dataset. [See the rhythm data](https://cedclinic.com/cannabis-heart-rhythm-jacc-study/)[How You Take Cannabis Changes What It Does](https://cedclinic.com/cannabis-routes-of-administration-onset-duration/) Route determines how fast peak concentrations arrive, which drives the acute hemodynamic response. [Compare the routes](https://cedclinic.com/cannabis-routes-of-administration-onset-duration/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Does cannabis raise your heart rate? Yes, reliably and in a dose-dependent way. A faster heart rate is the most consistent acute cardiovascular effect of cannabis and is well described in the cardiology literature. The effect is larger and faster with inhaled routes because peak blood concentrations arrive within minutes. Regular users develop partial tolerance to the cardiac response, meaning it becomes less noticeable rather than absent. Does cannabis raise or lower blood pressure? Both, depending on posture and timing. The classic description is supine hypertension with postural hypotension: blood pressure rises while lying down and falls on standing. The postural drop explains the lightheadedness many people report after using cannabis and is a genuine fall risk in older adults. Cannabidiol has its own effect, lowering resting systolic pressure in a small controlled study of healthy volunteers. Can cannabis trigger a heart attack? The evidence points that way for the hour after use. A case-crossover analysis of 3,882 myocardial infarction patients published in Circulation found risk elevated 4.8 times over baseline in the 60 minutes following cannabis use, with the elevation falling off rapidly afterward. The authors described cannabis as a rare trigger, meaning the relative risk is substantial while the absolute event remains uncommon in low-risk people. Is cannabis linked to stroke? Several analyses find an association. A 2025 meta-analysis in Heart pooling 24 pharmacoepidemiological studies reported a stroke risk ratio of 1.20. A large survey analysis found daily cannabis use associated with stroke at an adjusted odds ratio of 1.42, rising to 2.16 among respondents who had never smoked tobacco. A Mendelian randomization study suggested an effect specifically on small vessel stroke after adjustment. Is CBD safe for the heart? CBD is not hemodynamically inert. In a randomized crossover study of nine healthy men, a single 600 mg dose reduced resting systolic blood pressure by about 6 mmHg and stroke volume by about 8 mL, with a compensatory rise in heart rate. That is a small single-dose study in healthy young men, but it establishes real activity. Anyone taking blood pressure medication should discuss CBD with their prescriber. Does the cardiovascular risk depend on how often you use cannabis? The population data suggest it does. In the Behavioral Risk Factor Surveillance System analysis, daily use carried the highest odds of myocardial infarction, stroke, and the composite outcome, with proportionally lower odds at fewer days of use per month. Meta-analyses that treat cannabis as ever-used versus never-used more often return non-significant results, which is consistent with frequency carrying the signal. Does smoking versus eating cannabis change the cardiac risk? Route changes the acute response and probably changes chronic risk, though the second part is less well studied. Inhalation produces faster and higher peak concentrations, which drives a sharper hemodynamic response. Combustion also introduces vascular injury unrelated to cannabinoids. Most of the existing risk literature involves smoked cannabis and cannot cleanly separate combustion from the cannabinoids themselves. Should I tell my cardiologist I use cannabis? Yes, and tell them how often rather than simply that you do. Cannabis affects heart rate and blood pressure, interacts with several cardiovascular medications, and is relevant to perioperative and anesthesia planning. The 2025 Heart meta-analysis concluded that clinicians should investigate cannabis use in all patients presenting with serious cardiovascular disorders. Frequency of use is the detail the risk evidence actually describes. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).